GMP News

Medical Cannabis in Germany: From the BtMG to the Cannabis Act?

According to a draft version for the German Cannabis Law (Cannabisgesetz, CannG), cannabis for medical purposes will no longer fall within the scope of the Narcotics Law (Betäubungsmittelgesetz, BtMG). What changes may result?

More

Draft of USP Chapter <711> Dissolution (PDG harmonized document) Published for Comments

In the Pharmacopeial Forum, PF 49(3), a proposal of a revised USP General Chapter <711> Dissolution has been published for comments. The background to the publication is the efforts of international harmonization of monographs and general analytical methods of the European, Japanese, and United States pharmacopeias. The new draft represents the Pharmacopeial Discussion Group (PDG) harmonized document.

More

Revision of USP Chapters <782> Vibrational Circular Dichroism Spectroscopy and <1782> Vibrational Circular Dichroism Spectroscopy - Theory and Practice

In the Pharmacopeial Forum, PF 49(3), proposals of revised USP General Chapters <782> Vibrational Circular Dichroism Spectroscopy and <1782> Vibrational Circular Dichroism Spectroscopy - Theory and Practice were published for comments.

More

Dead Leg in Pharmaceutical Water System leads to Warning Letter

Due to deficiencies found in an FDA inspection, a US pharmaceutical manufacturer has now received a Warning Letter. Among other things, a dead leg in the pharmaceutical water system is listed as a deficiency.

More

Cloud Computing: Is a check list for the assessment of a Cloud Service Provider sufficient?

Financial and organizational advantages speak for the use of cloud services in the pharmaceutical environment. However, potential risks and regulatory restrictions should be known. Nine experts from industry and regulatory authorities answer an extensive catalog of questions from various topic areas. Question 12: Will it be sufficient to send a check list for the assessment of the CSP - for instance Amazon and Microsoft?

More

New EMA Guidelines and Revisions in GMP Area

EMA has published a new version of the "3-year work plan for the Quality domain". This also includes partly renewed timeframes for the revision of GMP specifications.

More

USP Publishes Draft on Quality Requirements for Cannabis

The USP previously announced to elaborate a chapter on quality considerations for Cannabis. Now the draft chapter <1568> Quality Considerations for Cannabis and Cannabis-Derived Products for Clinical Research has been published in PF 49.3. Comments can be sent to the USP until end of July.

More

USP Draft for Dronabinol Capsules

The USP published the draft monograph for Dronabinol Capsules in PF 49.3. Comments can be sent to the USP until end of July.

More

Herbal Medicines for Children

The EMA has published on its website an updated overview with recommendations for the use of herbal medicinal products (HMPs) in children.

More

EMA IRIS Guides updated again

In February and April 2023, the "IRIS guide to registration and RPIs" was updated again and is now valid as version 2.13. Like the "IRIS guide for applicants" and "IRIS guide to parallel distribution applicants", the latest versions of this document are available on the EMA website.

More

EMA updates Timelines of eAFs for Variations for Medicinal Products for Human Use

In future, submissions of variation notifications for medicinal products for human use are to be made exclusively via the electronic application forms (eAFs). The timelines for the full implementation of these systems have now been updated again and are listed on the EMA website in the PLM Portal (Product Lifecycle Management Portal).

More

CMDh: Update of Q&As on Renewals

The CMDh (Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human) updated the Q&A document on "Renewals" in March 2023 and published it on the HMA (Heads of Medicines Agencies) website in the CMDh - Questions & Answers section in April.

More

EDQM: Updates on CEP 2.0

As part of the implementation of the new "CEP 2.0", the EDQM has now provided further information on its website.  

More

Revised USP General Chapter <781> Optical Rotation published for Comments

In the Pharmacopeial Forum, PF 49(3), a proposal of a slightly revised USP General Chapter <781> Optical Rotation has been published for comments.

More

Switzerland: New Declaration of the Responsible Person for foreign Manufacturers

Swissmedic has specified the conditions for the submission of an audit report by the Responsible Person as proof of GMP compliance of foreign manufacturers.

More

FDA Warning Letter: Root Cause of Benzene Contamination not unterstood

The U.S. Food and Drug Administration (FDA) has recently published a new Warning Letter. An OTC manufacturer received information indicating that the finished drug products produced with isobutane propellants were contaminated with benzene. The company's own analyses as well as results of the FDA laboratory testing confirmed the presence of this impurity. The company failed to perform adequate investigations and so far, the root cause of the benzene contamination is not understood.

More

Cloud Computing: Audit / Remote audit of a Cloud Service Provider

Financial and organizational advantages speak for the use of cloud services in the pharmaceutical environment. However, potential risks and regulatory restrictions should be known. Nine experts from industry and regulatory authorities answer an extensive catalog of questions from various topic areas. Question 11: How many days must be planned for the audit of a CSP? Is it also possible to carry out a remote audit?

More

Do pharmaceutical Water Systems need a sterile Ventilating Filter?

Pharmaceutical water systems (PW and WFI) require a ventilating filter on the storage tank. It prevents dirty ambient air from being sucked into the system when water is withdrawn from the tank. This is often referred to as a sterile filter. However, there are numerous requirements for "real" sterile filtration according to the current EU GMP Annex 1. But is sterile filtration even necessary for this application?

More

EDQM: CEP Report

In March 2023, the EDQM once more prepared its "CERTIFICATION MONTHLY REPORT" on the topic of "CEPs" and has now published it in the newsroom of the EDQM website.

More

Biological Reactiviy - USP Chapter is undergoing Revision

The USP has recently published a revision of its Chapter <87> "Biological Reactivitiy Tests, In Vitro" for comments. One of the objectives is a better alignment with other relevant USP chapters.

More

MHRA's GCP Inspection Metrics

The MHRA published their GCP Inspections Metrics Report, covering the period from 1 April 2019 to 31 March 2020. Critical observations were related e.g. to data integrity, IMP management, protocol compliance, and pharmacovigilance.

More

New Definition of Pharmaceutical Grade Plastic Packaging Materials

The proposed USP General Chapter <1031> The Biocompatibility of Pharmaceutical Packaging Systems and their Materials of Construction has been published for comment in the current issue of Pharmacopeial Forum. It outlines a risk-based approach to biocompatibility evaluation.

More

FDA's Framework for Decentralized Clinical Trials

Following the previously published FDA guidance on externally controlled trials, the agency issued a Framework for the use of Digital Health Technologies (DHT).

More

WHO: Excipients GMP Guideline published for Comments

In March 2023, the WHO published the first draft of the guideline "WHO good manufacturing practices for excipients used in pharmaceutical products" on its website for comments. The public comment period ends on 26 May 2023.

More

GMP Update: Consequences from the New EU Commission Proposal

The EU Commission has published the proposal for the revision of the EU pharmaceutical legislation. The changes are to be regulated in a directive and a regulation. There are also GMP-relevant changes.

More

GMP Newsletter

Sign up for the free of charge newsletters.

Sign up now!

GMP Conferences by Topics